



# Next Generation Immunomedicines

BofA Securities 2022 Healthcare Conference  
May 10, 2022

# Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "may," "will," "potential," "expects," "believes," "intends," "hope," "towards," "forward," "later" and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the development plans for our immunomedicines, statements about the progress and evaluation and expected timing of results of NextCure's ongoing clinical trial of NC318, expectations regarding the potential benefits, activity, effectiveness and safety of NC318, expectations regarding the investigator initiated trial conducted by Yale, the expected timing of results of NextCure's ongoing clinical trial of NC410, the development plans for NC762, NextCure's financial guidance, expected upcoming milestones, and NextCure's plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure's business, including NextCure's clinical trials, third parties on which NextCure relies and NextCure's operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and no products approved for commercial sale; NextCure's history of significant losses; NextCure's need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure's FIND-IO™ platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including in Item 1A of NextCure's most recent Form 10-K, subsequent Form 10-Q and elsewhere in the Company's filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, except as required by law, even if expectations change.

# NextCure Highlights

NC318 (S15)



Phase 2

NC410 (LAIR-2)



Phase 1

NC762 (B7-H4)



Phase 1

NC525 (LAIR-1)



IND Q4 2022

## PIPELINE

*Progress*

- NC318 (S15): Phase 2 monotherapy & combo therapy
- NC410 (LAIR-2): Phase 1 monotherapy
- NC762 (B7-H4): Phase 1 monotherapy
- NC525 (LAIR-1): IND Q4 2022

## PRODUCT

*Strategy*

- Patient selection increasing probability of success
- Biomarkers for detecting early activity
- Potential for combination therapy
- FIND-IO discovery platform

## PEOPLE

*Experience*

- Experienced team
- Fully integrated GMP manufacturing team




## Significant Momentum & Milestones in 2022

**NC318, NC410, NC762**  
On Track

**BUILDING PIPELINE**  
Momentum










**EXPERIENCED**  
Team

**RUNWAY**  
Q1 2024





# Advancing Product Development Pipeline


PROGRAMS	TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NEXT MILESTONE
PRODUCT CANDIDATES								
NC318	S15	 	Tumors and macrophages	NSCLC, BREAST, H&N				Phase 2 update Q4 2022
NC318 Anti-PD-1 Combo*	S15	 	Tumors and macrophages	NSCLC				Initial Data 2H 2022
NC410	LAIR-2		ECM	NSCLC, H&N, GASTRIC, CRC, CERVICAL				Phase 1 update 2H 2022
NC762	B7-H4		Tumors	NSCLC, BREAST, OVARIAN				Initial Phase 1 data 2H 2022
NC525	LAIR-1		Leukemic Stem Cells	AML				IND filing Q4 2022
DISCOVERY AND RESEARCH PROGRAMS								
Multiple Programs	Multiple Targets	 	Multiple cell types					IND filing in 2023
*Investigator-initiated (IIT) trial (Yale University)								

\*Investigator-initiated (IIT) trial (Yale University)

**Worldwide Rights to All Programs**

# NC318

Humanized Siglec-15 (S15) Monoclonal Antibody




Phase 2  
CLINICAL  
TRIALS

## BIOLOGY

- Decreases suppressive myeloid cells & pro-tumorigenic cytokines
- Promotes T cell function & IFN- $\gamma$  production

## MOA



## HIGHLIGHTS

- NSCLC, Breast, H&N
- Evidence of disease control
- Enhanced outcomes in S15+ patients

# NC410

LAIR-2 (Collagen-Binding) Fusion Protein Decoy




Phase 1/2  
CLINICAL  
TRIAL

## BIOLOGY

- Targets LAIR-1/LAIR-2 pathway
- Enhances T cell infiltration and tumor killing

## MOA




## HIGHLIGHTS

- Patient selection assay
- Evidence of immune activation
- Synergistic combinations
- 2021 posters & publications
  - ASCO
  - SITC
  - eLife
  - Frontiers in Immunology

# NC762

Humanized B7-H4 Monoclonal Antibody




Phase 1/2  
CLINICAL  
TRIAL

## BIOLOGY

- Unique mechanism of action
- Inhibits tumor cell growth & is not dependent on T cells
- NK cells enhance anti-tumor activity

## MOA




## HIGHLIGHTS

- Initiated Phase 1 trial
- IHC assay for patient selection
- Biomarkers
- AACR 2021 poster
- Initial Phase 1 data 2H 2022



# NC525

Humanized LAIR-1 Monoclonal Antibody




NC525  
IND Q4 2022

## BIOLOGY


- LAIR-1 expression
  - High on AML blasts and leukemia stem cells (LSCs)
  - Minimal on hematopoietic stem and progenitor cells (HSPCs)

## MOA

Kills AML Blast Cells & LSCs



Spares HSPCs



## HIGHLIGHTS

- Inhibits colony formation of AML LSCs *in vitro*
- Inhibits AML growth in MV4-11 derived xenografts
- Restricts AML progression in patient-derived xenografts



## Significant Momentum & Milestones in 2022

### ON TRACK

NC318, NC410, NC762

### MOMENTUM

Building Pipeline

### TEAM

Experienced

### Q1 2024

Runway

